{
    "nctId": "NCT00784680",
    "briefTitle": "ATAC - Quality of Life Sub-Protocol",
    "officialTitle": "A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women",
    "overallStatus": "COMPLETED",
    "conditions": "Quality of Life",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "N/A",
    "enrollmentCount": 308,
    "primaryOutcomeMeasure": "Time to withdrawal",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Eligible for entry into the main ATAC trial 1033IL/0029\n* Completion of a baseline questionnaire\n\nExclusion Criteria:\n\n* Excluded from entry into the main ATAC trial (1033IL/0029)\n* If, in the investigators opinion, the patient would be unable to comply with this sub-protocol due to psychiatric or literacy reasons",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}